<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc">eid</journal-id><journal-title>Emerging Infectious Diseases</journal-title><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9866753</article-id><article-id pub-id-type="pmc">2640245</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Does restricted distribution limit access and coverage of yellow fever vaccine in the United States?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Monath</surname><given-names>T. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Giesberg</surname><given-names>J. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fierros</surname><given-names>E. G.</given-names></name></contrib></contrib-group><aff>OraVax Inc., Cambridge, Massachusetts, USA.</aff><pub-date pub-type="ppub"><season>Oct-Dec</season><year>1998</year></pub-date><volume>4</volume><issue>4</issue><fpage>698</fpage><lpage>702</lpage></article-meta></front></article>